Advancing Autologous CAR-T Cell Therapy Development Through Translatable in Vivo Murine Xenograft Tumour Models: A Pathologist’s Perspective
- Understanding the rationale behind selecting the most relevant and translatable in vivo models
- Leveraging these models to better understand safety and efficacy of CAR-T cells in solid tumours
- Understanding the safety endpoints of the model to advance the clinical translations of this CAR-T therapy